{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:55:49Z","timestamp":1767966949189,"version":"3.49.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,5,20]],"date-time":"2014-05-20T00:00:00Z","timestamp":1400544000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s10147-014-0697-z","type":"journal-article","created":{"date-parts":[[2014,5,19]],"date-time":"2014-05-19T01:33:22Z","timestamp":1400463202000},"page":"198-206","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial"],"prefix":"10.1007","volume":"20","author":[{"given":"Naohito","family":"Shimoyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuo","family":"Gomyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Katakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakuni","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Yukitoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Shimoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,5,20]]},"reference":[{"key":"697_CR1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0304-3959(90)90004-W","volume":"41","author":"RK Potenoy","year":"1990","unstructured":"Potenoy RK, Hagen NA (1990) Breakthrough pain: definition, prevalence and characteristics. Pain 41:273\u2013281","journal-title":"Pain"},{"key":"697_CR2","first-page":"1103","volume":"13","author":"MA Simmonds","year":"1999","unstructured":"Simmonds MA (1999) Management of breakthrough pain due to cancer. Oncology (Williston Park) 13:1103\u20131108","journal-title":"Oncology (Williston Park)"},{"key":"697_CR3","first-page":"354","volume":"30","author":"D Bennett","year":"2005","unstructured":"Bennett D, Burton AW, Fishman S et al (2005) Consensus panel recommendations for the assessment and management of breakthrough pain: Part 2. Management. Pharmacol Ther 30:354\u2013361","journal-title":"Pharmacol Ther"},{"key":"697_CR4","unstructured":"Actiq SPC (2012) Cephalon Ltd, UK"},{"key":"697_CR5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ejps.2003.07.002","volume":"20","author":"S Bredenberg","year":"2003","unstructured":"Bredenberg S, Duberg M, Lennernas B et al (2003) In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. Eur J Pharm Sci 20:327\u2013334","journal-title":"Eur J Pharm Sci"},{"key":"697_CR6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00000542-199802000-00006","volume":"88","author":"JB Streisand","year":"1998","unstructured":"Streisand JB, Busch MA, Egan TD et al (1998) Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anesthesiology 88:305\u2013309","journal-title":"Anesthesiology"},{"key":"697_CR7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2125.2004.02264.x","volume":"59","author":"B Lennernas","year":"2004","unstructured":"Lennernas B, Hedner T, Holmberg M et al (2004) Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol 59:249\u2013253","journal-title":"Br J Clin Pharmacol"},{"key":"697_CR8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/bmjspcare-2011-000037","volume":"1","author":"R England","year":"2011","unstructured":"England R, Maddocks M, Manderson C et al (2011) How practical are transmucosal fentanyl products for breakthrough cancer pain? novel use of placebo formulations to survey user opinion. BMJ Support Palliat Care 1:349\u2013351","journal-title":"BMJ Support Palliat Care"},{"key":"697_CR9","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.1998.16.10.3238","volume":"16","author":"JM Christie","year":"1998","unstructured":"Christie JM, Simmonds M, Patt R et al (1998) Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 16:3238\u20133245","journal-title":"J Clin Oncol"},{"key":"697_CR10","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0885-3924(01)00306-2","volume":"22","author":"R Payne","year":"2011","unstructured":"Payne R, Coluzzi P, Hart L et al (2011) Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain. J Pain Symptom Manag 22:575\u2013583","journal-title":"J Pain Symptom Manag"},{"issue":"Suppl 11","key":"697_CR11","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1002\/1097-0142(19931201)72:11+<3393::AID-CNCR2820721606>3.0.CO;2-O","volume":"72","author":"NI Cherny","year":"1993","unstructured":"Cherny NI, Portenoy RK (1993) Cancer pain management: current strategy. Cancer 72(Suppl 11):3393\u20133415","journal-title":"Cancer"},{"key":"697_CR12","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/jjco\/hyt099","volume":"43","author":"T Yamaguchi","year":"2013","unstructured":"Yamaguchi T, Shima Y, Morita T et al (2013) Clinical guideline for pharmacological management of cancer pain: the Japanese society of palliative medicine recommendations. Jpn J Clin Oncol 43:896\u2013909","journal-title":"Jpn J Clin Oncol"},{"key":"697_CR13","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1185\/03007990903368310","volume":"25","author":"RL Rauck","year":"2009","unstructured":"Rauck RL, Tark M, Reyes E et al (2009) Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin 25:2877\u20132885","journal-title":"Curr Med Res Opin"},{"key":"697_CR14","unstructured":"Abstral SPC (2013) ProStrakan Ltd, Galashiels, UK"},{"key":"697_CR15","unstructured":"Abstral SPC (2013) Galena Biopharma, Inc., Lake Oswego, US"},{"key":"697_CR16","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1553-2712.1996.tb03402.x","volume":"3","author":"KH Todd","year":"1996","unstructured":"Todd KH, Funk JP (1996) The minimum clinically important difference in physician-assigned visual analog pain scores. Acad Emerg Med 3:142\u2013146","journal-title":"Acad Emerg Med"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-014-0697-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-014-0697-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-014-0697-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T15:35:56Z","timestamp":1565451356000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-014-0697-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,20]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["697"],"URL":"https:\/\/doi.org\/10.1007\/s10147-014-0697-z","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,20]]}}}